BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1631 related articles for article (PubMed ID: 32962206)

  • 1. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
    Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
    Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
    Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids
    Nörz D; Mullins CS; Smit DJ; Linnebacher M; Hagel G; Mirdogan A; Siekiera J; Ehm P; Izbicki JR; Block A; Thastrup O; Jücker M
    Anticancer Res; 2021 May; 41(5):2257-2275. PubMed ID: 33952452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the PI3K/Akt/mTor pathway using
    Phyu SM; Tseng CC; Fleming IN; Smith TA
    Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
    Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
    Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
    J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
    Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.
    Chang L; Wu P; Senthilkumar R; Tian X; Liu H; Shen X; Tao Z; Huang P
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):59-72. PubMed ID: 26109148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
    Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
    Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Ou DL; Lee BS; Lin LI; Liou JY; Liao SC; Hsu C; Cheng AL
    Mol Cancer; 2014 Jan; 13():2. PubMed ID: 24387108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
    Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
    Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
    Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.